Neuroprotection via anti-inflammatory effects

"Neuroprotection via anti-inflammatory effects" is not a specific molecule or receptor but rather describes a **therapeutic strategy** or mechanism by which various agents protect neural tissue from damage by reducing inflammation. This approach involves targeting the inflammatory processes that contribute to neuronal injury in conditions such as stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neurological disorders[2][3][4]. Key molecular players in this process include microglia and astrocytes—immune cells of the central nervous system—which release pro-inflammatory cytokines like TNF-alpha and IL-6 during pathological states. Excessive activation of these cells leads to chronic inflammation and neuronal damage. Drugs that provide neuroprotection via anti-inflammatory effects often act by inhibiting microglial activation, suppressing pro-inflammatory cytokine production, blocking transcription factors such as NF-kappaB involved in inflammation signaling pathways, or enhancing antioxidant defenses[1][2]. Examples of drug classes with these properties include thiazolidinediones (PPAR-gamma agonists), natural compounds like catalpol and ursolic acid, non-steroidal anti-inflammatory drugs (NSAIDs), chemokine blockers, cerebrolysin, among others[1][2][3][4]. These agents may also modulate oxidative stress pathways alongside their anti-inflammatory actions. Because "neuroprotection via anti-inflammatory effects" is a broad therapeutic concept rather than a single defined target molecule or receptor—and encompasses multiple possible molecular targets—it does not have canonical names/abbreviations nor direct interacting drugs/mechanisms/biomarkers/safety concerns without specifying the underlying target(s) involved.